Neuronetics Announces Positive TMS Coverage Policies to Expand Patient Access to NeuroStar TMS Therapy for Mental Health
11 juil. 2022 16h46 HE
|
Neuronetics
MALVERN, Pa., July 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics to Present at the William Blair 42nd Annual Growth Stock Conference
25 mai 2022 16h30 HE
|
Neuronetics
MALVERN, Pa., May 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve...
New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy
17 mai 2022 08h31 HE
|
Neuronetics
Published in Brain Stimulation Journal, study describes insights from world’s largest depression registry MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
Neuronetics Reports First Quarter 2022 Financial and Operating Results
12 mai 2022 07h30 HE
|
Neuronetics
MALVERN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics and Transformations Care Network Announce Extended Commercial Partnership
11 mai 2022 16h30 HE
|
Neuronetics
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting
11 mai 2022 08h31 HE
|
Neuronetics
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Files Federal Lawsuit Against Brainsway for Misleading Psychiatrists and Patients
11 mai 2022 08h00 HE
|
Neuronetics
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder
10 mai 2022 08h31 HE
|
Neuronetics
MALVERN, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 mai 2022 16h30 HE
|
Neuronetics
MALVERN, Pa., May 06, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
NeuroStar Advanced Therapy for Mental Health Announces Partnership with Mental Health Advocate and Former Major League Baseball Player Drew Robinson
03 mai 2022 12h59 HE
|
Neuronetics
A Media Snippet accompanying this announcement is available by clicking on the image or link below: MALVERN, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial...